Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 7Lymphoma 7Sezary Syndrome 5Immunoblastic Lymphadenopathy 5Recurrence 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Mycosis Fungoides 4Melanoma 4Lymphoma, Non-Hodgkin 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Lymphocytic, Chronic, B-Cell 4Subcutaneous panniculitis-like T-cell lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Hodgkin Disease 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Skin Neoplasms 2Primary Myelofibrosis 2Neoplasms, Plasma Cell 2Myeloproliferative Disorders 2Multiple Myeloma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, Extranodal NK-T-Cell 2Leukemia, Myelomonocytic, Chronic 2

Interventions

denileukin diftitox 2Nivolumab 2sargramostim 1peginterferon alfa-2b 1Prednisone 1Phenobarbital 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Irinotecan 1Introns 1Infliximab 1Etoposide 1Dexamethasone 1Cyclosporine 1Cyclophosphamide 1Cisplatin 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Prednisone × Dermatologic × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡